SCHEMBL1818643

SCHEMBL1818643

CC(Oc1ccccc1)(C(N)=O)c1ccccc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
TSHR P16473 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPT P10636 3/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 3/20 0.38
HSD17B10 Q99714 3/20 0.38
ALOX15 P16050 1/20 0.38
PPARA Q07869 4/20 0.35
PPARG P37231 2/20 0.35
KDM4E B2RXH2 2/20 0.35
PARP10 Q53GL7 1/20 0.35
KCNN4 O15554 2/20 0.35
KIF11 P52732 1/20 0.35
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HSD11B1 P28845 1/20 0.33
HSD11B2 P80365 1/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1819040 0.84 MAPT (0.41) MAPTKMT2APPARAPPARGPARP10
SCHEMBL1821869 0.83 KCNN4 (0.51) MAPTKMT2APPARAPPARGPARP10
SCHEMBL1823517 0.83 MAPT (0.40) ALDH1A1MAPTKMT2AHPGDPPARA
SCHEMBL1819713 0.83 MAOB (0.42) MAPTKMT2AHPGDKCNN4MEN1
SCHEMBL1821619 0.81 CTNNB1 (0.49) MAPTKMT2AHSD17B10PPARGKDM4E
SCHEMBL1818709 0.81 KMT2A (0.44) ALDH1A1MAPTKMT2AHPGDKDM4E
SCHEMBL1817766 0.80 CYP2C19 (0.38) ALDH1A1MAPTKMT2APPARAPPARG
SCHEMBL1820578 0.80 KMT2A (0.38) ALDH1A1TSHRTDP1MAPTKMT2A
SCHEMBL1819565 0.80 MAPT (0.38) ALDH1A1TSHRTDP1MAPTKMT2A
SCHEMBL27757832 0.80 MAPT (0.55) ALDH1A1MAPTKMT2AALOX15PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 ALDH1A1 406/4885TSHR 1695/4885TDP1 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.